DUBLIN--(BUSINESS WIRE)--The "Isothermal Nucleic Acid Amplification Technology/INAAT Market by Product (Assay & Kit, System), Application (Infectious disease [HIV, Influenza], Blood Screening), Type (LAMP, SDA, NASBA, HDA), End User, Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The global isothermal nucleic acid amplification technology (INAAT) market size is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period.
The rising prevalence of infectious diseases and the introduction of newer pathogens, and the cost-benefits of INAAT is expected to drive the overall growth of the INAAT market.
The major factors driving the growth of this market include the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT. However, the extensive usage and reliance on PCR are expected to limit the adoption of INAAT.
Assay, kits and reagents segment is expected to grow at the highest CAGR during the forecast period.
Based on the product, the market is segmented broadly into assay, kits, and reagents, and systems. The assay, kits, and reagents segment is projected to grow at the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; the rising prevalence of infectious diseases; the continuous launch of newer, faster, and more reliable POC products; increasing approvals of CLIA-waived tests; accessibility to a wide range of reagents; repeated purchase of reagents; and the increasing use of reagents in therapeutics, basic research, and assay development.
TMA is expected to grow at CAGR during the forecast period.
Based on type, the INAAT market is segmented into TMA, LAMP, SDA, HDA, NASBA, and other INAAT technologies. The TMA segment is expected to be the fastest-growing segment during the forecast period due to the growing reliance on POC diagnosis in hospitals and blood banks.
Infectious disease diagnosis segment to grow at the highest CAGR during the forecast period.
The INAAT market, by the applications, has been categorized into infectious disease diagnosis, blood screening, and other applications (cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis). Infectious disease diagnosis segment to grow at the highest CAGR during the forecast period owing to the increasing number of infectious disease diagnostic tests carried out and rising prevalence of infectious diseases, among others.
Asia Pacific region to account for the largest share of the global INAAT market in 2019.
Asia Pacific is expected to be the fastest-growing segment during the forecast period. Factors such as the sustained economic growth in several Asia Pacific countries, the rising disposable income, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including INAAT) for research and clinical applications, high infectious disease burden, availability of low-cost POC INAAT assays, and growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment in Asia Pacific countries are expected to support market growth in this region during the forecast period.
Key Benefits of Buying the Report:
- The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall INAAT market and its subsegments.
- This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.
- The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities
Key Topics Covered:
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Research Data
2.2 Market Estimation Methodology
2.3 Data Triangulation
2.4 Research Assumptions
3 Executive Summary
4 Premium Insights
4.1 Isothermal Nucleic Acid Amplification Technology Market Overview
4.2 North America: Isothermal Nucleic Acid Amplification Technology Market Share, By Product & Country (2019)
4.3 Isothermal Nucleic Acid Amplification Technology Market, By End User
4.4 Isothermal Nucleic Acid Amplification Technology Market, By Application
4.5 Isothermal Nucleic Acid Amplification Technology Market, By Type
5 Market Overview
5.2 Market Dynamics
6 Isothermal Nucleic Acid Amplification Technology Market, By Product
6.2 Assays, Kits, and Reagents
7 Isothermal Nucleic Acid Amplification Technology Market, By Type
7.2 Transcription-Mediated Amplification
7.3 Loop-Mediated Isothermal Amplification
7.4 Strand Displacement Amplification
7.5 Helicase-Dependent Amplification
7.6 Nucleic Acid Sequence-Based Amplification
7.7 Other Technologies
8 Isothermal Nucleic Acid Amplification Technology Market, By Application
8.2 Infectious Disease Diagnosis
8.3 Blood Screening
8.4 Other Applications
9 Isothermal Nucleic Acid Amplification Technology Market, By End User
9.3 Reference Laboratories
9.4 Academic & Research Institutes
9.5 Other End Users
10 Isothermal Nucleic Acid Amplification Technology Market, By Region
10.2 North America
10.4 Asia Pacific
11 Competitive Landscape
11.2 Market Ranking Analysis, 2018
11.3 Competitive Leadership Mapping
11.4 Competitive Scenario
12 Company Profiles
12.1 Grifols, S.A.
12.2 Hologic, Inc.
12.3 Abbott Laboratories, Inc.
12.4 Becton, Dickinson and Company
12.5 Meridian Bioscience
12.6 EIKEN CHEMICALS Co., Ltd.
12.7 Quidel Corporation
12.8 Tecan Trading AG
12.9 Diasorin Group S.P.A
12.11 Illumina, Inc.
12.12 Thermo Fisher Scientific, Inc.
12.13 Biomrieux SA
12.14 GE Healthcare
12.15 Other Companies
12.15.1 New England Biolabs, Inc.
12.15.2 Lucigen Corporation
12.15.3 Ustar Biotechnologies Ltd.
12.15.4 TwistDx Limited
12.15.5 Mast Group Ltd.
12.15.6 Genomtec SA
For more information about this report visit https://www.researchandmarkets.com/r/4bmq7x